Atopic Dermatitis

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

Soong discussed the role of allergist's in atopic dermatitis care at a recent HCPLive clinical forum.

Explore the long-term safety and efficacy of JAK inhibitors in atopic dermatitis, enhancing patient care and clinician confidence.

Healthcare providers discuss the importance of effective communication when switching patients from biologics to JAK inhibitors.

Clinicians discuss the importance of patient-centered treatment decisions and the need to address therapeutic inertia in managing chronic conditions.

Explore the evolving landscape of atopic dermatitis treatment, focusing on advanced therapies and long-term patient management strategies.

Healthcare professionals explore effective questioning techniques to uncover deeper emotional and physical impacts of skin pain in patients.

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.

This post-hoc analysis highlights nemolizumab’s long-term efficacy and safety in adolescents with moderate-to-severe atopic dermatitis.

Study finds eczema onset at 4–6 months, greater severity, and longer duration linked to lower odds of outgrowing food allergies in children.

Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

These topline results from the ADHAND trial highlight tralokinumab’s use in adults with atopic dermatitis with moderate-to-severe hand involvement.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

The interview highlights the evolution of atopic dermatitis treatment, emphasizing options beyond topical steroids.

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.